Name: 글로벌 시장 동향
SKU: CD1107
Availability: InStock

보고서 요약(국문)

항균제 감수성 검사 시장 규모
전 세계 항균제 감수성 검사 시장은 2023년 34억 6,754만 달러에 달했으며, 2024년부터 2031년까지 연평균 5.9%의 성장률을 보이며 2031년에는 5조 4,302억 달러에 이를 것으로 예상됩니다.
항균제 감수성 검사(AST)는 의료 기술자 또는 임상 실험실 과학자가 개별 환자에게 특히 효과적인 항균 요법을 결정하기 위해 수행하는 실험실 기술입니다. 광범위하게 사용될 경우, 병원, 진료소 및 국가 감염병 관리 및 예방 프로그램에서 제공하는 치료 서비스를 평가하는 데 도움이 됩니다.
항균제 감수성 검사 시장 동향
전 세계 항균제 감수성 검사 시장의 성장은 기술 발전, 감염병 유병률 증가, 정부 및 민간 기관의 연구 개발 자금 증가, 그리고 의료 인프라 발전에 의해 주도됩니다.

전 세계적으로 항생제 감수성 검사에 대한 수요가 증가함에 따라 시장 성장이 촉진되고 있습니다.
항생제 내성(AMR)은 전 세계 공중 보건에 심각한 위협으로 대두되었습니다. 세계보건기구(WHO)에 따르면, 항생제 내성은 전 세계 모든 지역에서 위험할 정도로 높은 수준으로 증가하고 있으며, 이로 인해 질병 발생률과 사망률이 높아지고 있습니다. 또한, 세계은행은 내성균 감염이 세계 경제 위기를 초래하여 2050년까지 매년 2,800만 명이 극심한 빈곤에 빠지고, 세계 경제에 연간 1조 달러의 손실을 가져올 수 있다고 추산합니다.
항생제 내성을 정확하고 신속하게 감지하고 적절한 항생제 치료를 시행하는 것은 항생제 관리와 함께 AMR의 발생 및 확산을 억제하는 데 매우 중요합니다. 세균 감염 치료를 위한 최적의 치료법은 모든 임상 미생물학 실험실에서 일상적으로 수행하는 항생제 감수성 검사(AST) 결과에 따라 결정됩니다. 검사 결과는 지역별 항생제 감수성 양상을 파악하는 데 도움을 주어 의료 전문가가 가장 효과적인 항생제 치료법을 선택할 수 있도록 지원합니다. 예를 들어, 병원균의 항생제 내성률(AMR)이 20%를 초과하는 경우, 해당 약물은 감염 치료를 위한 단일 경험적 요법으로 투여해서는 안 됩니다.
또한, 시장 참여자들은 인수 및 신제품 출시와 같은 시장 전략을 채택하고 있습니다. 예를 들어, 2022년 4월, 비오메리외(BIOMÉRIEUX)는 스페시픽 다이애그노스틱스(Specific Diagnostics)를 인수하기로 합의했습니다. 미국에 본사를 둔 이 비상장 회사는 양성 혈액 배양 검체에서 직접 표현형 항생제 감수성 검사(AST) 결과를 제공하는 SPECIFIC REVEAL Rapid AST 시스템이라는 신속 항생제 감수성 검사(AST) 시스템을 개발했습니다. 또한, 2020년 2월에는 바이오래드 래버러토리스(Bio-Rad Laboratories, Inc.)가 검사 결과의 유효성과 일관성을 보장하는 데 도움이 되는 진단 제품을 개발 및 제조하는 이그젝트 다이애그노스틱스(Exact Diagnostics)를 인수했습니다. 이그젝트 다이애그노스틱스 인수를 통해 바이오래드 래버러토리스는 장기 이식, 호흡기 질환, 바이러스학, 미생물학, 성병 및 매개체 전염병 분야에서 포괄적인 분자 품질 관리 제품 카탈로그를 확보하게 되었습니다.

항균제 감수성 검사 제품/기기의 단점은 시장 성장을 저해할 것입니다.
높은 비용 외에도 분자 생물학적 방법의 주요 단점은 사용 가능한 프로브로만 표적화된 내성 유전자를 검출할 수 있다는 점과 내성 유전자가 반드시 내성 표현형 발현과 연관되지 않기 때문에 내성을 과대평가할 수 있다는 점입니다. 또한 자동 및 반자동 시스템은 고유한 장점과 한계를 가지고 있으며, 항균제, 소프트웨어 버전 및 카드에 따라 결과가 크게 달라집니다. 따라서 일부 시스템은 특정 약물에 대한 감수성 프로파일을 정확하게 분류하는 데 신뢰성이 떨어져 감수성 범주를 잘못 분류하는 경우가 있습니다. 또한 접종량이 적을수록 이러한 시스템의 결과에 상당한 영향을 미쳐 잘못된 감수성 결과가 보고되는 것으로 보입니다.
COVID-19가 항균제 감수성 검사 시장에 미치는 영향 분석
COVID-19 팬데믹 기간 동안 항균제 내성(AMR) 관련 협력 활동이 제한되고 자금 지원이 감소했으며, 간호, 의료 및 공중 보건 인력의 부족으로 AMR 감시, 예방 및 통제에 차질이 발생했습니다. 임상 및 실험실 표준 연구소(CLSI)의 2020년 보고서에 따르면, 환자의 감염 여부, 바이러스 및 세균 감염원, 병원체 및 항생제 감수성 프로파일을 신속하게 진단하는 것이 매우 중요합니다. 실험실은 의심되는 병원체를 빠르게 식별하고 치료에 대한 감수성을 판단함으로써 급변하는 환경에서 올바른 임상적 결정을 내리는 데 도움을 줄 수 있습니다. 이는 개별 환자의 치료 결과를 크게 개선할 뿐만 아니라 불필요한 항생제 사용을 방지하는 데에도 기여합니다. 또한, 손 소독제와 표면 세정제를 포함한 소독제의 사용 증가로 인해 향후 몇 년 동안 병원성 미생물의 항생제 내성률이 급증할 것으로 예상됩니다.
항균제 감수성 검사 시장 부문 분석
자동화된 실험실 기기 부문은 예측 기간(2024-2031년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
제품 유형별:
감수성 검사 디스크
MIC 스트립
감수성 플레이트
자동화된 실험실 기기
소모품
방법별:
액체 희석법
신속 자동화법
디스크 확산법
경사 확산법
분자 검사법
검사 유형별:
항균제
항진균제
항기생충제
기타
응용 분야별:
임상 진단
신약 개발 및 연구
기타
최종 사용자별:
진단 센터 및 병원
제약 및 생명공학 회사
임상시험수탁기관(CRO)
연구 및 학술 기관
자동화된 실험실 기기 부문이 가장 큰 시장 점유율을 차지합니다. 2022년 Antibiotics Journal에 발표된 논문에 따르면, 현재 시판 중인 신속 항생제 감수성 검사(AST) 기술에는 미세희석 감수성 검사 기반의 자동 및 반자동 장비가 포함됩니다. 예를 들어, Phoenix 시스템은 임상 미생물학 실험실에서 균 동정 및 항생제 감수성 검사에 널리 사용되고 있습니다. 감수성 검사 원리는 산화환원 지시약(알라마르 블루 또는 레사주린 염료)을 사용하여 다양한 농도의 항생제 존재 하에서 세균의 성장을 감지하는 것입니다. 또한, MicroScan WalkAway Plus 시스템은 광범위한 그람 양성 및 그람 음성 호기성 세균에 대해 정확하고 신속한 동정 및 감수성 결과를 제공합니다.
더 나아가, 시판 중인 MicroScan WalkAway 시스템의 1세대 모델은 AutoSCAN-3입니다. 최신 버전인 AutoSCAN-4와 AutoSCAN-WalkAway는 개선되었으며 냉장이 필요 없는 건식 패널을 사용합니다. AutoSCAN-WalkAway 시스템은 세균 효소 활성을 감지하고 96개의 패널을 동시에 처리할 수 있습니다. 첨단 자동화 항균제 감수성 검사(AST) 시스템의 보급은 전 세계 시장 성장을 촉진하고 있습니다.
항균제 감수성 검사 시장 지역별 점유율
북미 지역은 전 세계 항균제 감수성 검사 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미는 항균제 감수성 검사 시장을 주도하고 있으며, 예측 기간 동안에도 이러한 추세가 지속될 것으로 예상됩니다. 북미 항균제 감수성 검사 시장의 성장은 기술 발전, 감염병 증가, 신제품 출시 증가, 주요 업체들의 존재 등에 기인합니다.
bioMérieux에 따르면 미국에서는 매년 280만 건 이상의 항생제 내성 감염이 발생합니다. 내성균의 출현은 항생제의 부적절한 사용으로 인해 악화되고 가속화되는 심각한 현상입니다. 북미 지역의 항균제 감수성 검사 증가가 시장 성장을 견인하고 있습니다.
또한, 시장 참여 업체들은 인수 및 신제품 출시와 같은 시장 전략을 채택하고 있습니다. 예를 들어, 2022년 5월 Accelerate Diagnostics, Inc.는 새로운 Accelerate Arc Module 및 BC 키트의 상용화를 발표했습니다. Accelerate Arc Module 및 BC 키트는 인라인 원심분리 및 자동 샘플 준비 기술의 새로운 응용 분야로, 혈액 배양 키트와 함께 사용하면 정제된 미생물 세포 현탁액을 생성하여 MALDI 스포팅 플레이트로 직접 옮길 수 있습니다. 또한, Accelerate PhenoTest BC 키트 AST 구성은 실험실에서 현재 표준 치료 방법보다 며칠 더 빨리 양성 혈액 배양 검체에서 직접 동정 및 항균제 감수성 검사 결과를 보고할 수 있도록 합니다.
항균제 감수성 검사 기업 및 경쟁 환경
항균제 감수성 검사 시장은 지역 및 글로벌 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 시장 성장에 기여하는 주요 기업으로는 bioMérieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, Synbiosis 등이 있습니다. 주요 기업들은 신제품 출시, 인수, 협력 등 다양한 성장 전략을 통해 글로벌 항균제 감수성 검사 시장의 성장을 견인하고 있습니다.

예를 들어,
2021년 10월 Thermo Fisher Scientific과 Q-linea는 6시간 이내에 정확한 최소억제농도(MIC) 데이터를 제공하는 신속 항균제 감수성 검사(AST) 시스템인 ASStar 기술을 출시했습니다. 기존 AST 기법은 결과를 얻는 데 최대 72시간이 소요될 수 있습니다.

bioMérieux SA
개요:
bioMérieux SA는 임상 실험실에서 효과적인 결과를 제공하는 데 사용되는 미생물학 솔루션을 제공하는 기업입니다. 감염 관리, 다제내성 예방 및 관리, 환자 치료 결과 개선에 있어 진단 시간과 치료 효과가 매우 중요하기 때문입니다.
제품 포트폴리오:
VITEK 2: 대부분의 일반적인 미생물(약 300종)에 대한 항생제 감수성 검사를 자동화한 시스템입니다. 분석 소프트웨어와 독창적인 소형 소모품의 조합으로 몇 시간 내에 결과를 제공합니다. 이 검사 시스템은 다양한 미생물에 적용 가능합니다.
글로벌 항균제 감수성 검사 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Antimicrobial Susceptibility Testing Market Size
The Global Antimicrobial Susceptibility Testing Market reached US$ 3,467.54 million in 2023 and is expected to reach US$ 5,430.20 billion by 2031, growing at a CAGR of 5.9% during the forecast period 2024-2031.
Antimicrobial susceptibility testing (AST) is a laboratory technique conducted by medical technologists or clinical laboratory scientists to determine which antimicrobial regimen is particularly efficacious for individual patients. On an enormous scale, it helps evaluate treatment services delivered by hospitals, clinics, and national programs for managing and preventing infectious diseases.
Antimicrobial Susceptibility Testing Market Dynamics
The global antimicrobial susceptibility testing market growth is driven by technological advancement, a rising prevalence of infectious disease, rising funding for research and development from government and private organizations, and advancements in healthcare infrastructure.
The rising need for antimicrobial susceptibility testing across the globe drives the market growth
Antimicrobial resistance (AMR) has appeared as a major threat to public health worldwide. According to the World Health Organization (WHO), antibiotic resistance is rising to dangerously high levels in all regions of the world, leading to raised morbidity and mortality. In addition, the World Bank estimates that drug-resistant infections could induce a global economic crisis, leading to 28 million people who could be moved into extreme poverty every year by 2050, with an overall cost to the global economy of USD 1 trillion per year.
Exact and quick detection of resistance to antimicrobial drugs and following appropriate antimicrobial treatment, incorporated with antimicrobial stewardship, are crucial for controlling the emergence and spread of AMR. The best therapeutic option for treating bacterial infections relies on the results of AST, a part of the routine work of all clinical microbiological laboratories. Reports provide an understanding of local antimicrobial susceptibility patterns, helping healthcare professionals select the most effective antibiotic therapy. For instance, if the AMR rate of a pathogen is above 20%, that drug should not be administered as a single empiric therapy for infection treatment.
In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in April 2022, BIOMÉRIEUX agreed to acquire Specific Diagnostics. This privately held U.S.-based company has developed a rapid antimicrobial susceptibility test (AST), SPECIFIC REVEAL Rapid AST system that delivers phenotypic AST directly from positive blood cultures. Moreover, in February 2020, Bio-Rad Laboratories, Inc. acquired Exact Diagnostics, a developer and manufacturer of diagnostic products that help ensure the validity and consistency of test results. With the acquisition of Exact Diagnostics, Bio-Rad Laboratories, Inc. has access to a comprehensive catalog of molecular quality control products in transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.
The drawbacks of antimicrobial susceptibility testing products/instruments will hamper the growth of the market
However, besides high costs, major drawbacks of molecular methods are the detection of the resistance genes targeted only by the available probes and overestimating resistance because the resistance gene is not necessarily associated with the expression of a resistance phenotype. In addition, automated and semi-automated systems have inherent advantages and limitations, and the results vary widely by antimicrobial drugs, software versions, and cards. Hence, some systems are unreliable for correctly categorizing susceptibility profiles for certain drugs, leading to wrong classifications of susceptibility categories. It appears that small inoculum size significantly influences the outcome of these systems, with false susceptibilities being reported.
COVID-19 Impact Analysis on  Antimicrobial Susceptibility Testing Market
During the COVID-19 pandemic, the limited ability to work with AMR partnerships decreased funding, and reduced availability of nursing, medical, and public health staff affected AMR surveillance, prevention, and control. According to the Clinical and Laboratory Standards Institute (CLSI) 2020 report, there is a critical need for rapid diagnostics to determine if a patient has an infection, determine viral and bacterial sources, and identify the etiologic agent and its susceptibility profile. Labs can guide the right-first-time clinical decisions in fast-paced environments by fast identifying the suspected pathogen and determining its susceptibility to treatment. Not only can this significantly improve individual outcomes, but the approach also avoids unnecessary antibiotic use. In addition, increased use of disinfectants, including hand sanitizers and surface cleaners, is anticipated to cause inflated rates of antimicrobial resistance in pathogenic microbes in the coming years.
Antimicrobial Susceptibility Testing Market Segment Analysis
The automated laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
By Product Type:
Susceptibility Testing Disks
MIC Strips
Susceptibility Plates
Automated Laboratory Instruments
Consumables
By Method:
Broth Dilution Method
Rapid Automated Method
Disk Diffusion Method
Gradient Diffusion Method
Molecular Testing Method
By Test Type:
Antibacterial
Antifungal
Antiparasitics
Others
By Application:
Clinical Diagnosis
Drug Discovery and Development
Others
By End-User:
Diagnostic Centers and Hospitals
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs)
Research and Academic Institutes
The automated laboratory instruments segment accounts for the largest market share. As per the article published in Antibiotics Journal in 2022, current technologies for rapid AST are available in the market, including automated and semi-automated devices based on microdilution susceptibility testing. For instance, the Phoenix System is widely accepted and used in clinical microbiology laboratories for identification and antimicrobial susceptibility testing. The principle of determining the susceptibility is based on using an oxidation-reduction indicator (Alamar blue or resazurin dye) and detecting bacterial growth in the presence of various concentrations of the antimicrobial agent. Also, The MicroScan WalkAway plus System provides accurate and rapid identification and susceptibility results for a wide range of Grampositive and Gram-negative aerobic bacteria.
In addition, The first generation of the MicroScan WalkAway System available on the market is the AutoSCAN-3. The new versions of instruments Auto-ACAN-4 and AutoSCAN-WalkAway are improved and use dry panels that do not need refrigeration. The AutoSCAN-WalkAway system detects bacterial enzymatic activity and can process 96 panels simultaneously. The availability of advanced and automated systems for AST boosts the market worldwide.
Antimicrobial Susceptibility Testing Market Geographical Share
North America region holds the largest market share of the global Antimicrobial Susceptibility Testing market
North America dominates the market for antimicrobial susceptibility testing and is expected to show a similar trend over the forecast period. The growth of the North American antimicrobial susceptibility testing market can be attributed to technological advancements, rising infectious disease, increasing launching of products and the presence of key players.
According to the bioMérieux organization, more than 2.8 million antibiotic-resistant infections occur annually in the United States. The emergence of resistant bacteria is an unpretending phenomenon worsened and accelerated by the improper use of antibiotics. Rising antimicrobial susceptibility testing in the region drives the market.
In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in May 2022, Accelerate Diagnostics, Inc. announced the commercialization of its new Accelerate Arc Module and BC kit. The Accelerate Arc Module and BC kit is a new application of inline centrifugation and automated sample prep techniques, which, together with the blood culture kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. In addition, Accelerate PhenoTest BC kit AST configuration enables laboratories to report identification and antimicrobial susceptibility test results directly from positive blood cultures days earlier than current standard-of-care methods.
Antimicrobial Susceptibility Testing Companies and Competitive Landscape
The antimicrobial susceptibility testing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are bioMérieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, and Synbiosis, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global antimicrobial susceptibility testing market.
For instance,
In October 2021, Thermo Fisher Scientific and Q-linea launched ASTar Technology, a quick antimicrobial susceptibility testing (AST) system that provides true minimum inhibitory concentration (MIC) data in less than 6 hours. Conventional AST techniques might take up to 72 hours to obtain findings.
bioMérieux SA
Overview:
bioMérieux SA is an organization that provides solutions for microbiology, which is used in clinical labs to provide effective results because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.
Product Portfolio:
VITEK 2: It is an automated susceptibility testing system capable of determining the extensive majority of routine organisms (around 300 microorganisms). This system gives results within hours due to the combination of analysis software and an original, miniaturized consumable. This testing system is available for a various range of microorganisms.
The global antimicrobial susceptibility testing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

상세 목차

1. Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Infectious Diseases
4.1.1.2. Technological Advancements
4.1.2. Restraints:
4.1.3. Strict Regulatory Procedures
4.1.4. Opportunity
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Manual Antimicrobial Susceptibility Testing Products*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
7.2.3. Susceptibility Testing Disks
7.2.4. MIC Strips
7.2.5. Susceptibility Plates
7.3. Automated Laboratory Instruments
7.4. Consumables
8. By Method
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
8.1.2. Market Attractiveness Index, By Method
8.2. Broth Dilution Method*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
8.3. Rapid Automated Method
8.4. Disk Diffusion Method
8.5. Gradient Diffusion Method
8.6. Molecular Testing Method
9. By Test Type
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
9.1.2. Market Attractiveness Index, By Test Type
9.2. Antibacterial*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
9.3. Antifungal
9.4. Antiparasitics
9.5. Others
10. By Application
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Clinical Diagnosis*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
10.3. Drug Discovery and Development
10.4. Others
11. By End User
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Diagnostic Centers and Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
11.3. Pharmaceutical and Biotechnology Companies
11.4. Contract Research Organizations (CROs)
11.5. Research and Academic Institutes
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030, By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. The U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
13. Competitive Landscape
13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Product Benchmarking
14. Company Profiles
14.1. bioMérieux S.A.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Key Highlights
14.1.4. Financial Overview
14.2. Danaher Corporation
14.3. Becton, Dickinson and Company
14.4. Thermo Fisher Scientific Inc.
14.5. Bio-Rad Laboratories Inc.
14.6. Merck Group
14.7. HiMedia Laboratories
14.8. Alifax Holding S.p.A.
14.9. Creative Diagnostics
14.10. Synbiosis (*LIST NOT EXHAUSTIVE)
15. DataM Intelligence
15.1. Appendix
15.2. About Us and Services
15.3. Contact Us

언급된 주요 기업들

bioMérieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics

표 목록 (Tables)

List of Tables

Table 01 Global Antimicrobial Susceptibility Testing Market Value, By Product Type, 2021, 2025 & 2029 ($ Million)

Table 02 Global Antimicrobial Susceptibility Testing Market Value, By Method, 2021, 2025 & 2029 ($ Million)

Table 03 Global Antimicrobial Susceptibility Testing Market Value, By Test Type, 2021, 2025 & 2029 ($ Million)

Table 04 Global Antimicrobial Susceptibility Testing Market Value, By Application, 2021, 2025 & 2029 ($ Million)

Table 05 Global Antimicrobial Susceptibility Testing Market Value, By End User, 2021, 2025 & 2029 ($ Million)

Table 06 Global Antimicrobial Susceptibility Testing Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 07 Global Antimicrobial Susceptibility Testing Market Value, By Product Type, 2021, 2025 & 2029 ($ Million)

Table 08 Global Antimicrobial Susceptibility Testing Market Value, By Product Type, 2020-2029 ($ Million)

Table 09 Global Antimicrobial Susceptibility Testing Market Value, By Method, 2021, 2025 & 2029 ($ Million)

Table 10 Global Antimicrobial Susceptibility Testing Market Value, By Method, 2020-2029 ($ Million)

Table 11 Global Antimicrobial Susceptibility Testing Market Value, By Test Type, 2021, 2025 & 2029 ($ Million)

Table 12 Global Antimicrobial Susceptibility Testing Market Value, By Test Type, 2020-2029 ($ Million)

Table 13 Global Antimicrobial Susceptibility Testing Market Value, By Application, 2021, 2025 & 2029 ($ Million)

Table 14 Global Antimicrobial Susceptibility Testing Market Value, By Application, 2020-2029 ($ Million)

Table 15 Global Antimicrobial Susceptibility Testing Market Value, By End User, 2021, 2025 & 2029 ($ Million)

Table 16 Global Antimicrobial Susceptibility Testing Market Value, By End User, 2020-2029 ($ Million)

Table 17 Global Antimicrobial Susceptibility Testing Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 18 Global Antimicrobial Susceptibility Testing Market Value, By Region, 2020-2029 ($ Million)

Table 19 North America Antimicrobial Susceptibility Testing Market Value, By Product Type, 2020-2029 ($ Million)

Table 20 North America Antimicrobial Susceptibility Testing Market Value, By Method, 2020-2029 ($ Million)

Table 21 North America Antimicrobial Susceptibility Testing Market Value, By Test Type, 2020-2029 ($ Million)

Table 22 North America Antimicrobial Susceptibility Testing Market Value, By Application, 2020-2029 ($ Million)

Table 23 North America Antimicrobial Susceptibility Testing Market Value, By End User, 2020-2029 ($ Million)

Table 24 North America Antimicrobial Susceptibility Testing Market Value, By Country, 2020-2029 ($ Million)

Table 25 South America Antimicrobial Susceptibility Testing Market Value, By Product Type, 2020-2029 ($ Million)

Table 26 South America Antimicrobial Susceptibility Testing Market Value, By Method, 2020-2029 ($ Million)

Table 27 South America Antimicrobial Susceptibility Testing Market Value, By Test Type, 2020-2029 ($ Million)

Table 28 South America Antimicrobial Susceptibility Testing Market Value, By Application, 2020-2029 ($ Million)

Table 29 South America Antimicrobial Susceptibility Testing Market Value, By End User, 2020-2029 ($ Million)

Table 30 South America Antimicrobial Susceptibility Testing Market Value, By Country, 2020-2029 ($ Million)

Table 31 Europe Antimicrobial Susceptibility Testing Market Value, By Product Type, 2020-2029 ($ Million)

Table 32 Europe Antimicrobial Susceptibility Testing Market Value, By Method, 2020-2029 ($ Million)

Table 33 Europe Antimicrobial Susceptibility Testing Market Value, By Test Type, 2020-2029 ($ Million)

Table 34 Europe Antimicrobial Susceptibility Testing Market Value, By Application, 2020-2029 ($ Million)

Table 35 Europe Antimicrobial Susceptibility Testing Market Value, By End User, 2020-2029 ($ Million)

Table 36 Europe Antimicrobial Susceptibility Testing Market Value, By Country, 2020-2029 ($ Million)

Table 37 Asia-Pacific Antimicrobial Susceptibility Testing Market Value, By Product Type, 2020-2029 ($ Million)

Table 38 Asia-Pacific Antimicrobial Susceptibility Testing Market Value, By Method, 2020-2029 ($ Million)

Table 39 Asia-Pacific Antimicrobial Susceptibility Testing Market Value, By Test Type, 2020-2029 ($ Million)

Table 40 Asia-Pacific Antimicrobial Susceptibility Testing Market Value, By Application, 2020-2029 ($ Million)

Table 41 Asia-Pacific Antimicrobial Susceptibility Testing Market Value, By End User, 2020-2029 ($ Million)

Table 42 Asia-Pacific Antimicrobial Susceptibility Testing Market Value, By Country, 2020-2029 ($ Million)

Table 43 Middle East & Africa Antimicrobial Susceptibility Testing Market Value, By Product Type, 2020-2029 ($ Million)

Table 44 Middle East & Africa Antimicrobial Susceptibility Testing Market Value, By Method, 2020-2029 ($ Million)

Table 45 Middle East & Africa Antimicrobial Susceptibility Testing Market Value, By Test Type, 2020-2029 ($ Million)

Table 46 Middle East & Africa Antimicrobial Susceptibility Testing Market Value, By Application, 2020-2029 ($ Million)

Table 47 Middle East & Africa Antimicrobial Susceptibility Testing Market Value, By End User, 2020-2029 ($ Million)

Table 48 bioMérieux S.A.: Overview

Table 49 bioMérieux S.A.: Product Portfolio

Table 50 bioMérieux S.A.: Key Developments

Table 51 Danaher Corporation: Overview

Table 52 Danaher Corporation: Product Portfolio

Table 53 Danaher Corporation: Key Developments

Table 54 Becton, Dickinson and Company: Overview

Table 55 Becton, Dickinson and Company: Product Portfolio

Table 56 Becton, Dickinson and Company: Key Developments

Table 57 Thermo Fisher Scientific Inc.: Overview

Table 58 Thermo Fisher Scientific Inc.: Product Portfolio

Table 59 Thermo Fisher Scientific Inc.: Key Developments

Table 60 Bio-Rad Laboratories Inc.: Overview

Table 61 Bio-Rad Laboratories Inc.: Product Portfolio

Table 62 Bio-Rad Laboratories Inc.: Key Developments

Table 63 Merck Group: Overview

Table 64 Merck Group: Product Portfolio

Table 65 Merck Group: Key Developments

Table 66 HiMedia Laboratories: Overview

Table 67 HiMedia Laboratories: Product Portfolio

Table 68 HiMedia Laboratories: Key Developments

Table 69 Alifax Holding S.p.A.: Overview

Table 70 Alifax Holding S.p.A.: Product Portfolio

Table 71 Alifax Holding S.p.A.: Key Developments

Table 72 Creative Diagnostics: Overview

Table 73 Creative Diagnostics: Product Portfolio

Table 74 Creative Diagnostics: Key Developments

Table 75 Synbiosis: Overview

Table 76 Synbiosis: Product Portfolio

Table 77 Synbiosis: Key Developments

그림 목록 (Figures)

List of Figures

Figure 01 Global Antimicrobial Susceptibility Testing Market Share, By Product Type, 2020 & 2029 (%)

Figure 02 Global Antimicrobial Susceptibility Testing Market Share, By Method, 2020 & 2029 (%)

Figure 03 Global Antimicrobial Susceptibility Testing Market Share, By Test Type, 2020 & 2029 (%)

Figure 04 Global Antimicrobial Susceptibility Testing Market Share, By Application, 2020 & 2029 (%)

Figure 05 Global Antimicrobial Susceptibility Testing Market Share, By End User, 2020 & 2029 (%)

Figure 06 Global Antimicrobial Susceptibility Testing Market Share, By Region, 2020 & 2029 (%)

Figure 07 Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 08 Global Antimicrobial Susceptibility Testing Market Y-o-Y Growth, By Product Type, 2020-2029 (%)

Figure 09 Manual Antimicrobial Susceptibility Testing Products: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 10 Automated Laboratory Instruments: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 11 Consumables: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 12 Global Antimicrobial Susceptibility Testing Market Y-o-Y Growth, By Method, 2020-2029 (%)

Figure 13 Broth Dilution Method: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 14 Rapid Automated Method: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 15 Disk Diffusion Method: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 16 Gradient Diffusion Method: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 17 Molecular Testing Method: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 18 Global Antimicrobial Susceptibility Testing Market Y-o-Y Growth, By Test Type, 2020-2029 (%)

Figure 19 Antibacterial: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 20 Antifungal: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 21 Antiparasitics: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 22 Others: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 23 Global Antimicrobial Susceptibility Testing Market Y-o-Y Growth, By Application, 2020-2029 (%)

Figure 24 Clinical Diagnosis: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 25 Drug Discovery and Development: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 26 Others: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 27 Global Antimicrobial Susceptibility Testing Market Y-o-Y Growth, By End User, 2020-2029 (%)

Figure 28 Diagnostic Centers and Hospitals: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 29 Pharmaceutical and Biotechnology Companies: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 30 Contract Research Organizations (CROs): Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 31 Research and Academic Institutes: Global Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 32 Global Antimicrobial Susceptibility Testing Market Y-o-Y Growth, By Region, 2020-2029 (%)

Figure 33 North America Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 34 North America Antimicrobial Susceptibility Testing Market Share, By Product Type, 2020 & 2029 (%)

Figure 35 North America Antimicrobial Susceptibility Testing Market Share, By Method, 2020 & 2029 (%)

Figure 36 North America Antimicrobial Susceptibility Testing Market Share, By Test Type, 2020 & 2029 (%)

Figure 37 North America Antimicrobial Susceptibility Testing Market Share, By Application, 2020 & 2029 (%)

Figure 38 North America Antimicrobial Susceptibility Testing Market Share, By End User, 2020 & 2029 (%)

Figure 39 North America Antimicrobial Susceptibility Testing Market Share, By Country, 2020 & 2029 (%)

Figure 40 South America Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 41 South America Antimicrobial Susceptibility Testing Market Share, By Product Type, 2020 & 2029 (%)

Figure 42 South America Antimicrobial Susceptibility Testing Market Share, By Method, 2020 & 2029 (%)

Figure 43 South America Antimicrobial Susceptibility Testing Market Share, By Test Type, 2020 & 2029 (%)

Figure 44 South America Antimicrobial Susceptibility Testing Market Share, By Application, 2020 & 2029 (%)

Figure 45 South America Antimicrobial Susceptibility Testing Market Share, By End User, 2020 & 2029 (%)

Figure 46 South America Antimicrobial Susceptibility Testing Market Share, By Country, 2020 & 2029 (%)

Figure 47 Europe Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 48 Europe Antimicrobial Susceptibility Testing Market Share, By Product Type, 2020 & 2029 (%)

Figure 49 Europe Antimicrobial Susceptibility Testing Market Share, By Method, 2020 & 2029 (%)

Figure 50 Europe Antimicrobial Susceptibility Testing Market Share, By Test Type, 2020 & 2029 (%)

Figure 51 Europe Antimicrobial Susceptibility Testing Market Share, By Application, 2020 & 2029 (%)

Figure 52 Europe Antimicrobial Susceptibility Testing Market Share, By End User, 2020 & 2029 (%)

Figure 53 Europe Antimicrobial Susceptibility Testing Market Share, By Country, 2020 & 2029 (%)

Figure 54 Asia-Pacific Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 55 Asia-Pacific Antimicrobial Susceptibility Testing Market Share, By Product Type, 2020 & 2029 (%)

Figure 56 Asia-Pacific Antimicrobial Susceptibility Testing Market Share, By Method, 2020 & 2029 (%)

Figure 57 Asia-Pacific Antimicrobial Susceptibility Testing Market Share, By Test Type, 2020 & 2029 (%)

Figure 58 Asia-Pacific Antimicrobial Susceptibility Testing Market Share, By Application, 2020 & 2029 (%)

Figure 59 Asia-Pacific Antimicrobial Susceptibility Testing Market Share, By End User, 2020 & 2029 (%)

Figure 60 Asia-Pacific Antimicrobial Susceptibility Testing Market Share, By Country, 2020 & 2029 (%)

Figure 61 Middle East & Africa Antimicrobial Susceptibility Testing Market Value, 2020-2029 ($ Million)

Figure 62 Middle East & Africa Antimicrobial Susceptibility Testing Market Share, By Product Type, 2020 & 2029 (%)

Figure 63 Middle East & Africa Antimicrobial Susceptibility Testing Market Share, By Method, 2020 & 2029 (%)

Figure 64 Middle East & Africa Antimicrobial Susceptibility Testing Market Share, By Test Type, 2020 & 2029 (%)

Figure 65 Middle East & Africa Antimicrobial Susceptibility Testing Market Share, By Application, 2020 & 2029 (%)

Figure 66 Middle East & Africa Antimicrobial Susceptibility Testing Market Share, By End User, 2020 & 2029 (%)

Figure 67 bioMérieux S.A.: Financials

Figure 68 Danaher Corporation: Financials

Figure 69 Becton, Dickinson and Company: Financials

Figure 70 Thermo Fisher Scientific Inc.: Financials

Figure 71 Bio-Rad Laboratories Inc.: Financials

Figure 72 Merck Group: Financials

Figure 73 HiMedia Laboratories: Financials

Figure 74 Alifax Holding S.p.A.: Financials

Figure 75 Creative Diagnostics: Financials

Figure 76 Synbiosis: Financials

글로벌 항균제 감수성 시험 시장 – 2024-2031년

Global Antimicrobial Susceptibility Testing Market - 2024-2031